INT52346

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 1995
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 2.56
Pain Relevance 0.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

enzyme regulator activity (Sln)
Anatomy Link Frequency
axillary 1
SLN 1
RLN 1
lymph 1
intestinal lumen 1
Sln (Rattus norvegicus)
Pain Link Frequency Relevance Heat
anesthesia 7 94.96 High High
imagery 9 94.32 High High
Pain 7 94.16 High High
Bioavailability 60 64.88 Quite High
transdermal 108 50.00 Quite Low
Inflammation 55 5.00 Very Low Very Low Very Low
cINOD 6 5.00 Very Low Very Low Very Low
carrageenan induced 6 5.00 Very Low Very Low Very Low
rheumatoid arthritis 6 5.00 Very Low Very Low Very Low
Osteoarthritis 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Recurrence 16 97.84 Very High Very High Very High
Breast Cancer 32 95.60 Very High Very High Very High
Cancer 126 92.92 High High
Disease 22 87.64 High High
Metastasis 39 83.04 Quite High
Age-related Macular Degeneration 2 79.76 Quite High
Toxicity 5 78.32 Quite High
Oropharyngeal Neoplasms 14 71.12 Quite High
Head & Neck Cancer 8 52.56 Quite High
Diabetes Mellitus 24 46.24 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The slower release of drug from SLN and NLC enriched carbopol gel maintained the drug concentration for longer period of time.
Localization (release) of SLN
1) Confidence 0.69 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2651881 Disease Relevance 0 Pain Relevance 0
The direct exposure of SLN/NLC dispersion to diffusion media and quick release of drug may account for rapid initial release in SLN/NLC dispersions.
Localization (release) of SLN
2) Confidence 0.69 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2651881 Disease Relevance 0 Pain Relevance 0
The slower release of drug from SLN and NLC carbopol gels maintained the drug concentration for longer period of time.
Localization (release) of SLN
3) Confidence 0.69 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2651881 Disease Relevance 0 Pain Relevance 0
A different release kinetic was observed for the SLN dispersions and SLN gel formulations.
Localization (release) of SLN
4) Confidence 0.65 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2651881 Disease Relevance 0 Pain Relevance 0
B1 (NLC) (63.45%) and A1 (SLN) gel (54.85%) have minimum drug release with release rate constants of 2.7527 and 2.4488%/cm2/h, respectively.
Localization (release) of SLN
5) Confidence 0.65 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2651881 Disease Relevance 0 Pain Relevance 0
The direct exposure of SLN/NLC dispersion to diffusion media and quick release of drug may account for rapid initial release in SLN/NLC dispersions.
Localization (release) of SLN
6) Confidence 0.65 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2651881 Disease Relevance 0 Pain Relevance 0
METHODS: We performed a systematic review of the literature for studies concerning the late morbidity of patients who had undergone SLNB alone or SLNB followed by ALND when SLN metastases were found.
Localization (metastases) of SLN
7) Confidence 0.64 Published 2009 Journal Eur. J. Cancer Section Body Doc Link 19285858 Disease Relevance 0.09 Pain Relevance 0
CONCLUSIONS: Our data confirm the feasibility of single radiotracer administration for both occult lesion and SLN localization as well as the usefulness of SLND in staging early breast cancer.
Localization (localization) of SLN in SLN
8) Confidence 0.64 Published 2002 Journal Tumori Section Body Doc Link 12365388 Disease Relevance 0 Pain Relevance 0
The in vitro release of all the four batches of SLN (F1 to F4) were carried out, which showed an interesting biphasic release with an initial burst effect in the 1st h drug release was 15.18%, 16.2%, 16.22% and 17.34% for F1, F2, F3 and F4, respectively.
Localization (release) of SLN
9) Confidence 0.54 Published 2008 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2792476 Disease Relevance 0 Pain Relevance 0
This knowledge can be used to adjust degradation of SLN and consequently drug release in a controlled way (Olbrich and Muller 1999).
Localization (release) of SLN
10) Confidence 0.53 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.08 Pain Relevance 0.03
This may be related with the typical biphasic drug release pattern with an initial burst and prolonged release from SLN, characterized by a microcrystal matrix structure (Hu et al 2002; Wissing et al 2004; Souto 2005).
Localization (release) of SLN
11) Confidence 0.53 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0 Pain Relevance 0
Insulin released from SLN in the intestinal lumen is able to be directly internalized as discussed above, being the first responsible for the physiological effect.
Localization (released) of SLN in intestinal lumen
12) Confidence 0.53 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0 Pain Relevance 0
The presence of insulin on the surface of SLN was not responsible for significant agglomeration, predicting absence of aggregation after oral administration.
Localization (surface) of SLN
13) Confidence 0.49 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0 Pain Relevance 0.05
Another advantage is the possibility to perform a scintigraphy beforehand to identify and localize the SLN before surgery.
Localization (localize) of SLN
14) Confidence 0.48 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2984381 Disease Relevance 0.39 Pain Relevance 0.19
With this technique there is no direct visualization of the lymph drainage pattern, but only indirect visualization of the SLN with the gamma probe.
Localization (visualization) of SLN in lymph
15) Confidence 0.45 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2984381 Disease Relevance 0.25 Pain Relevance 0
Despite a lower rate of SLN positivity in patients undergoing SLNB only, axillary recurrence was not observed and none of the 52 patients experienced axillary recurrence (median followup 4.8 years).
Localization (rate) of SLN in axillary associated with recurrence
16) Confidence 0.38 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3018621 Disease Relevance 1.35 Pain Relevance 0
Once localized and excised, the SLN(s) was sent immediately to the laboratory for frozen section examination.
Localization (localized) of SLN
17) Confidence 0.21 Published 2008 Journal World J Surg Oncol Section Body Doc Link PMC2443144 Disease Relevance 0.40 Pain Relevance 0.07
Furthermore, bilateral section of the ExSLN in five dogs significantly reduced tidal TCD by 48.7 +/- 24.4% (P < 0.05), and bilateral section of both the ExSLN and RLN resulted in slight phasic inward TCD (-0.06 +/- 0.05 mm).
Localization (section) of ExSLN in RLN
18) Confidence 0.01 Published 1995 Journal J. Appl. Physiol. Section Abstract Doc Link 7759411 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox